NCI Drug Dictionary

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

daunorubicin hydrochloride and cytarabine liposome
Patient Information
A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Daunorubicin hydrochloride and cytarabine liposome has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids. Check for active clinical trials using this agent. (NCI Thesaurus)

Synonym:cytarabine-daunorubicin liposome for injection
liposomal AraC-daunorubicin CPX-351
liposomal cytarabine-daunorubicin
liposomal cytarabine-daunorubicin CPX-351
liposome-encapsulated combination of daunorubicin and cytarabine
liposome-encapsulated daunorubicin-cytarabine
US brand name:Vyxeos
Code name:CPX-351